Option chain shows key data for Cyclerion Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cyclerion Therapeutics.

Cyclerion Therapeutics (NASDAQ:CYCN) Stock, Option Chain

Cyclerion Therapeutics

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Tesla Inc. TSLA

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

APLM

AREN

ATCH

CMAX

CYCN

ERNA

FLYE

LAZR

LBRT

MNDR

NTLA

QMMM

SMCI

SYTA

TSLA

VVPR

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

movers image

Intraday Update

ADTX

ADVM

AEHR

ALLR

AMIX

APVO

ASLN

ASML

ASST

CLIR

CRDO

FDMT

FIVE

FUBO

GPCR

GTLB

HNST

JBHT

LCFY

NAAS

NVDA

NVMI

OCTO

ONTO

QCOM

SAVA

SAVE

SCNI

SHIM

SIEB

SMTC

SNAP

SONM

TKNO

VKTX

VRPX

Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Penny Stocks

Small Cap

AMPE

BIOR

BODY

BTOG

CLSK

CRIS

DELL

DOMO

ESTC

FEBO

FTHM

GLBS

HCDI

IXHL

LMNR

MARA

MATV

MINM

MRVL

OLPX

OPEN

PACI

PATH

PIXY

POLA

PTON

SMFL

SNGX

TNON

ULTA

UPST

VTVT

VVOS

WHLR

WISH

ZUMZ

Gainers
	Harbor Custom Development, Inc.  (NASDAQ: HCDI) rose 74.2% to $1.50 after surging 24% on Thursday.


Why Genesco Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics Inc

ALBT

Avalon GloboCare Regains Nasdaq Compliance

5 analysts have shared their evaluations of STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $33.4, a high estimate of $36.00, and a low estimate of $30.00. Experiencing a 12.11% decline, the current average is now lower than the previous average price target of $38.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732197625_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive STMicroelectronics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Anthony Stoss</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$35.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to STMicroelectronics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of STMicroelectronics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for STMicroelectronics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of STMicroelectronics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on STMicroelectronics analyst ratings.</a>
<h2>Get to Know STMicroelectronics Better</h2>
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
<h3>Unraveling the Financial Story of STMicroelectronics</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining STMicroelectronics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -26.63% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: STMicroelectronics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.8% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): STMicroelectronics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.98%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): STMicroelectronics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.37%, the company may face hurdles in achieving optimal financial performance.
Debt Management: STMicroelectronics's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For STMicroelectronics's Future

Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-22. Here's what investors need to know before the announcement.
Analysts estimate that Destination XL Group will report an earnings per share (EPS) of $0.03. 
The market awaits Destination XL Group's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.05, leading to a 1.1% increase in the share price on the subsequent day.
Here's a look at Destination XL Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.09</td>
<td>0.04</td>
<td>0.06</td>
<td>0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.06</td>
<td>0.10</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>8.0%</td>
<td>2.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732197623_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Destination XL Group were trading at $2.5 as of November 19. Over the last 52-week period, shares are down 37.66%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on Destination XL Group</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Destination XL Group.
The consensus rating for Destination XL Group is Buy, derived from 1 analyst ratings. An average one-year price target of $4.0 implies a potential 60.0% upside.
<h3>Comparing Ratings with Competitors</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of ThredUp, Citi Trends and Tilly's, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, ThredUp is favoring an Outperform trajectory, with an average 1-year price target of $3.0, suggesting a potential 20.0% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Citi Trends, with an average 1-year price target of $17.0, implying a potential 580.0% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Tilly's, with an average 1-year price target of $6.0, suggesting a potential 140.0% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for ThredUp, Citi Trends and Tilly's are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Destination XL Group</td>
<td>Buy</td>
<td>-10.87%</td>
<td>$60.17M</td>
<td>1.53%</td>
</tr>
<tr>
<td>ThredUp</td>
<td>Outperform</td>
<td>-11.00%</td>
<td>$51.98M</td>
<td>-31.81%</td>
</tr>
<tr>
<td>Citi Trends</td>
<td>Buy</td>
<td>1.73%</td>
<td>$54.93M</td>
<td>-12.64%</td>
</tr>
<tr>
<td>Tilly's</td>
<td>Neutral</td>
<td>1.82%</td>
<td>$49.92M</td>
<td>-0.05%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Destination XL Group ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is at the top for Return on Equity.
<h3>About Destination XL Group</h3>
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets.
<h3>Destination XL Group's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Destination XL Group's revenue growth over 3 months faced difficulties. As of 31 July, 2024, the company experienced a decline of approximately -10.87%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Destination XL Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.91%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.53%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Destination XL Group's ROA stands out, surpassing industry averages. With an impressive ROA of 0.63%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Destination XL Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.13.
<a href="https://www.benzinga.com/quote/DXLG/earnings">To track all earnings releases for Destination XL Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

DXLG

Earnings Outlook For Destination XL Group

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 24.26% since its last report. The company recently reported that it has 888 thousand shares sold short, which is 1.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732197622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.77%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Molina Healthcare's Recent Short Interest

Mediaocean To Acquire Innovid For $3.15 Per Share In $500M Deal, Merging With Flashtalking To Create A Leading Independent Omnichannel Ad Tech Platform, Expected To Close In Early 2025

Discover Finl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) short percent of float has risen 12.72% since its last report. The company recently reported that it has 4.27 million shares sold short, which is 1.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.64 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Discover Finl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732197617_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Discover Finl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Discover Finl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Discover Finl's peer group average for short interest as a percentage of float is 7.51%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Discover Finl's Recent Short Interest

Global Blue Gr Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-22. Here's what investors need to know before the announcement.
Analysts estimate that Global Blue Gr Holding will report an earnings per share (EPS) of $0.03. 
Investors in Global Blue Gr Holding are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.06, leading to a 1.42% increase in the share price on the subsequent day.
Here's a look at Global Blue Gr Holding's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.08</td>
<td>0.07</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.02</td>
<td>0.01</td>
<td>0.06</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>14.000000000000002%</td>
</tr>
</tbody>
</table>

<h3>Market Performance of Global Blue Gr Holding's Stock</h3>
Shares of Global Blue Gr Holding were trading at $5.57 as of November 19. Over the last 52-week period, shares are up 24.89%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/GB/earnings">To track all earnings releases for Global Blue Gr Holding visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Global Blue Gr Holding

Providing a diverse range of perspectives from bullish to bearish, 29 analysts have published ratings on Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">11</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $126.83, along with a high estimate of $150.00 and a low estimate of $57.00. Observing a 10.56% increase, the current average has risen from the previous average price target of $114.72. 
<img src="https://www.benzinga.com/files/images/story/2024/1732197611_0_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Trade Desk. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$134.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$133.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$150.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Sell</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Vikram Kesavabhotla</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Clark Lampen</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$142.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Dan Salmon</td>
<td>New Street Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Michael Nathanson</td>
<td>MoffettNathanson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Reif Ehrlich</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$109.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Trade Desk. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Trade Desk compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Trade Desk's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Trade Desk's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TTD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Trade Desk analyst ratings.</a>
<h2>Delving into Trade Desk's Background</h2>
The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.
<h3>Breaking Down Trade Desk's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Trade Desk's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 27.32%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.99%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Trade Desk's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.74% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.77%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Trade Desk Stands With Analysts

American Finl Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFG#NYSE">AFG</a>) short percent of float has fallen 10.14% since its last report. The company recently reported that it has 893 thousand shares sold short, which is 1.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.13 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>American Finl Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732197611_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for American Finl Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing American Finl Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, American Finl Gr's peer group average for short interest as a percentage of float is 1.74%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(AFG) - Analyzing American Finl Gr's Short Interest

NMHIW

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

WIIM

Apollomics shares are trading lower after the company announced a 1-for-100 reverse stock split.

Cantor Fitzgerald analyst Yi Fu Lee reiterates Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Overweight and maintains $445 price target.

Price Target

Reiteration

PANW

Cantor Fitzgerald Reiterates Overweight on Palo Alto Networks, Maintains $445 Price Target

The International Criminal Court on Thursday issued arrest warrants for Israeli Prime Minister Benjamin Netanyahu and former defense minister Yoav Gallant, "for crimes against humanity and war crimes" in the <a href="https://www.benzinga.com/markets/emerging-markets/24/11/41757546/israels-netanyahu-fires-defense-minister-gallant-over-lack-of-trust-in-war-management-oi">ongoing war in Gaza</a>.
Netanyahu and Gallant intentionally deprived civilians in Gaza of food, water and medicine and medical supplies, as well as fuel and electricity, and used starvation as a method of warfare, the International Criminal Court alleges. 
The arrest warrants also allege both men deprived civilians in Gaza of fundamental rights, including the rights to life and health, and intentionally directed attacks against the civilian population of Gaza. The ICC&#8217;s Pre-trial Chamber I also found Netanyahu and Gallant are responsible for other inhumane acts. 
Israeli President Isaac Herzog called the arrest warrants a &#8220;dark day for justice&#8221; in a post on X, adding that the warrants are a &#8220;mockery&#8221; of those who fight for justice and &#8220;ignore the plight of the 101 Israeli hostages held in brutal captivity by Hamas in Gaza.&#8221; 
Herzog concluded: &#8220;This cynical exploitation of the international legal institutions reminds us once again of the need for true moral clarity in the face of an Iranian empire of evil that seeks to destabilize our region and the world, and destroy the very institutions of the free world.&#8221;
The court&#8217;s 124 member states would be obligated to arrest Netanyahu and Gallant if they entered those states, the Financial Times <a href="https://www.ft.com/content/0b62f17a-97db-4817-90f8-f98adead79f0">said</a> in a report, adding that the ICC has no means of enforcing this. 
The Details: The court also issued a warrant for Hamas military leader Mohammed Deif. Israeli officials say Deif was killed in an airstrike in Gaza in July. Prosecutors said they issued the warrant because they were not able to confirm whether he is dead or alive. 
The ICC rejected Israel's challenge to the court's jurisdiction over "the situation in the State of Palestine" and over Israeli nationals.
Read Next: <a href="https://www.benzinga.com/24/11/42107863/us-futures-head-lower-as-nvidia-reports-slowdown-in-quarterly-revenue-growth-expert-says-market-weakness-is-perfectly-normal-but-late-november-is-still-possible">US Futures Head Lower As Nvidia Earnings Fail To Impress Investors: Expert Says Market Weakness Is &#8216;Perfectly Normal,&#8217; But Late November Rally Is Still Possible</a>
The ICC said in a press release that the arrest warrants are classified as secret, but the chamber decided to release the information since the conduct "appears to be ongoing." The chamber also said it considers it in the best interest of the victims to be aware of the issuance of the warrants. 
Other Developments:  U.S. envoy Amos Hochstein is in Israel for talks with Israeli officials over a cease-fire in Lebanon. Hochstein left Beirut on Wednesday after two days of meetings with Lebanese officials, <a href="https://www.washingtonpost.com/world/2024/11/21/israel-war-news-hamas-gaza-palestine/">according</a> to The Washington Post. 
The United States vetoed a U.N. Security Council resolution put forward Wednesday that called for a cease-fire in Gaza because it was not contingent on the release of hostages still held and it did not condemn Hamas.
At least 44,056 people have been killed in Gaza during the war and 104,268 injured, the Post reported, citing the Gaza Health Ministry. At least 3,558 people have been killed and 15,123 injured in Lebanon, the report said, citing Lebanon&#8217;s health ministry. The organizations do not distinguish between civilians and combatants. 
Israel estimates that approximately 1,200 people were killed in the Oct. 7, 2023 attack and says 377 soldiers have been killed in its military operation in Gaza.
Image: Shutterstock.

Politics

Legal

Global

International Criminal Court Issues Arrest Warrants For Israeli Prime Minister Netanyahu, Gallant For War Crimes

AGFY

Agrify shares are trading lower. The company announced a non-brokered private placement at $22.30 per share for approximately $25.9 million in proceeds.

Barclays analyst Lauren Lieberman maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Overweight and raises the price target from $74 to $79.

BRBR

Barclays Maintains Overweight on BellRing Brands, Raises Price Target to $79

VNET

VNET Group shares are trading higher after the company reported Q3 EPS and revenue that rose year-over-year.

Barclays analyst Brian Morton maintains Bank of Montreal (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BMO#TSX">BMO</a>) with a Overweight and raises the price target from C$126 to C$143.

TSX:BMO

Barclays Maintains Overweight on Bank of Montreal, Raises Price Target to C$143

On Wednesday, the FDA granted accelerated approval to Jazz Pharmaceuticals plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) <a href="https://www.benzinga.com/pressreleases/24/11/n42101689/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-a" target="_blank" rel="noreferrer noopener">biliary tract cancer (BTC)</a>.
Ziihera&nbsp;was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41338366/jazz-pharmaceuticals-zepzelcatecentriq-combo-regimen-can-potentially-delay-disease-progression-ex" rel="noreferrer noopener">Jazz Pharmaceuticals&#8217; Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer</a>
The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.
Regulatory reviews of zanidatamab for BTC remain ongoing in China and Europe.
In late 2022, Zymeworks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) entered into a license and collaboration agreement with Jazz Pharmaceuticals for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan, and all other territories except for those Asia Pacific territories previously <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42106981/fda-grants-u-s-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previously-tr" rel="noreferrer noopener">licensed by Zymeworks</a>.
Under the Jazz license and collaboration agreement terms, Zymeworks has earned a milestone payment of $25 million based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.
Zymeworks says the approval represents the first FDA-approved therapy in its pipeline and validates the company&#8217;s Azymetric bispecific platform technology.
Price Action: JAZZ stock closed at $119.24 on Wednesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease" target="_blank" rel="noreferrer noopener">Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

JAZZ

ZYME

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework

Universal Technical Institute shares are trading higher after the company reported better-than-expected Q4 EPS and sales, and provided FY2024 revenue guidance above analyst estimates.

AppLovin shares are trading higher after the company priced a public offering of $3.55 billion in senior notes.

Cyclerion Therapeutics appoints Graul as President

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cyclerion Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycn-stock-quote/">CYCN</a>) just reported results for the fourth quarter of 2023.<ul><li>Cyclerion Therapeutics reported earnings per share of -$1.60.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/cycn-stock-earnings-cyclerion-therapeutics-for-q4-of-2023/">CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cyclerion Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycn-stock-quote/">CYCN</a>) just reported results for the first quarter of 2024.<ul><li>Cyclerion Therapeutics reported earnings per share of -62 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cycn-stock-earnings-cyclerion-therapeutics-for-q1-of-2024/">CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks are a bankruptcy filing, regulator approval, a public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Spectaire (NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/">SPEC</a>) stock is rocketing more than 111% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318405643&amp;type=PDF&amp;symbol=SPEC&amp;cdn=402f87b97cb330efbad1632693edb216&amp;companyName=Spectaire+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-20">letter, settlement and asset purchase agreements</a>.</li>



<li>Trinity Place (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tphs-stock-quote/">TPHS</a>) shares are soaring over 52% with heavy pre-market trading today.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) stock is surging more than 45% <a href="https://finance.yahoo.com/news/dermtech-files-voluntary-chapter-11-120500056.html">despite a recent bankruptcy filing</a>.</li>



<li>Sarepta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/srpt-stock-quote/">SRPT</a>) shares are gaining over 37% on <a href="https://www.marketwatch.com/story/sarepta-shares-soar-37-following-expanded-approval-for-elevidys-991d6de5?mod=home-page">expanded regulator approval</a>.</li>



<li>Kintara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktra-stock-quote/">KTRA</a>) stock is increasing 27% with strong early morning trading.</li>



<li>Qualigen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) shares are rising more than 16% with heavy trading today.</li>



<li>Unusual Machines (NYSEMKT:<a href="https://investorplace.com/stock-quotes/umac-stock-quote/">UMAC</a>) stock is climbing close to 16% despite a lack of news today.</li>



<li>Simpple (NASDAQ:<a href="https://investorplace.com/stock-quotes/sppl-stock-quote/">SPPL</a>) shares are jumping nearly 15% without any clear news today.</li>



<li>Lion Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/lghl-stock-quote/">LGHL</a>) stock is heading over 13% higher on Friday morning.</li>



<li>Solid Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/sldb-stock-quote/">SLDB</a>) shares are up more than 13% without any news to report.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Abacus Life (NASDAQ:<a href="https://investorplace.com/stock-quotes/abl-stock-quote/">ABL</a>) stock is diving over 23% after <a href="https://www.nasdaq.com/press-release/abacus-life-announces-pricing-public-offering-common-stock-2024-06-20">pricing a public offering</a>.</li>



<li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) shares are tumbling 20% on Friday morning.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) stock is taking a more than 18% beating with strong early morning trading.</li>



<li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) shares are sliding over 17% on Friday morning.</li>



<li>QXO (NASDAQ:<a href="https://investorplace.com/stock-quotes/qxo-stock-quote/">QXO</a>) stock is dropping 16% today.</li>



<li>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) shares are falling more than 15% <a href="https://investorplace.com/2024/06/why-is-reliance-global-reli-stock-up-283-today/">after a recent rally</a>.</li>



<li>MGO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgol-stock-quote/">MGOL</a>) stock is retreating over 14% <a href="https://investorplace.com/2024/06/why-is-mgo-global-mgol-stock-up-133-today/">following a rally yesterday</a>.</li>



<li>Cyclerion Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycn-stock-quote/">CYCN</a>) shares are decreasing 14% this morning.</li>



<li>Perfect (NYSE:<a href="https://investorplace.com/stock-quotes/perf-stock-quote/">PERF</a>) stock is slipping more than 12% today.</li>



<li>Scinai Immunotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/scni-stock-quote/">SCNI</a>) shares close out our pre-market stock movers down over 11% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-june-21st/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The latest announcement is out from Cyclerion Therapeutics (CYCN). Regina Graul, Ph.D., has been promoted to Chief Executive Officer, as announced ...

Cyclerion Therapeutics Appoints New CEO Regina Graul

Cyclerion Therapeutics names Regina Graul as CEO

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

DMTK

EYEN

IPDN

KAVL

KTRA

LGHL

MGOL

PERF

QLGN

RELI

SLDB

SPEC

SPPL

SRPT

TFFP

TPHS

UMAC

Management

Press Releases

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Cyclerion Appoints Regina Graul, Ph.D., as President

Regina Graul, Ph.D., Promoted to Chief Executive Officer

ABVC BioPharma

Comments

Cyclerion Therapeutics

Cyclerion Therapeutics (CYCN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga